^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PV-001-DV

    i
    Associations
    News

    Trials

    Company:
    PrimeVax
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma (NCT03990493)
    Phase 1
    PrimeVax Immuno-Oncology Inc.
    Not yet recruiting
    Last update posted :
    07/06/2023
    Initiation :
    04/01/2024
    Primary completion :
    09/30/2024
    Completion :
    12/31/2024
    PD-L1 • BRAF
    |
    PV-001-DC • PV-001-DV
    Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma (NCT03989895)
    Phase 1
    PrimeVax Immuno-Oncology Inc.
    Not yet recruiting
    Last update posted :
    07/06/2023
    Initiation :
    04/01/2024
    Primary completion :
    09/30/2024
    Completion :
    12/31/2024
    PD-L1
    |
    BRAF mutation
    |
    PV-001-DC • PV-001-DV